Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis

References

• Diabetes Statistics. American Diabetes Association 2012. Available at http://www.diabetes.org/diabetes-basics/diabetes-statistics. [Accessed 15 December 2011]
   Google Scholar
• National Diabetes Fact Sheet. Centers for Disease Control and Prevention 2012. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf [cited 2011 Dec 15];
   Google Scholar
• Byetta Press Release. US Food and Drug Administration 2012. [cited 2011 Dec 15];
   Google Scholar
• Januvia Press Release. US Food and Drug Administration 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770.htm. [Accessed 15 December 2011]
   Google Scholar
• Onglyza Press Release. US Food and Drug Administration 2012. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm174780.htm. [Accessed 15 December 2011]
   Google Scholar
• Linagliptin Press-Release. Boehringer Ingelheim 2012. Available at http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/03_may_2011_diabetes.html. [Accessed 15 December 2011]
   Google Scholar
• Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:511-27
   PubMed Web of Science ®Google Scholar
• Davidson JA. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010;85(12 Suppl):S27-S37
   PubMedGoogle Scholar
• Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009;124:113-38
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-S40
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Consumer Price Index. United States Department of Labor Bureau of Labor Statistics 2012 February 2A. Available at http://www.bls.gov/cpi/home.htm. [Accessed 4 December 2011]
   Google Scholar
• Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011;27:897-906
   PubMed Web of Science ®Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9
   PubMed Web of Science ®Google Scholar
• Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010;32:1756-67
   PubMed Web of Science ®Google Scholar
• Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products–liraglutide and exenatide–for the treatment of type 2 diabetes. J Med Econ 2010;13:655-61
   PubMedGoogle Scholar
• Bergenstal RM, Daniels G, Mann J, et al. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: rationale and study design. Diabetes 2011;60(1 Suppl):A612-3
   Google Scholar
• Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies–review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31
   PubMed Web of Science ®Google Scholar